5-Amino-1MQ

5-Amino-1MQ (5-amino-1-methylquinolinium) is not a peptide — it is a small molecule that works by blocking the enzyme NNMT (nicotinamide N-methyltransferase). Understanding why that matters requires understanding what NNMT does, because NNMT is one of the most underappreciated drivers of metabolic dysfunction and biological aging.

NNMT is an enzyme that methylates nicotinamide — a key NAD+ precursor — converting it into 1-methylnicotinamide (MNA) for excretion. In small amounts, this is normal metabolic housekeeping. The problem is that NNMT is dramatically overexpressed in the adipose tissue of obese individuals and in a range of cancer cell lines. When NNMT activity is elevated, it acts like a drain on the NAD+ precursor pool: it consumes the very nicotinamide that would otherwise be recycled into NAD+, reducing intracellular NAD+ levels and impairing the sirtuin and PARP activity that depends on it. The result is lower energy expenditure, impaired fat oxidation, and accelerated metabolic aging — a vicious cycle that compounds over time.

5-Amino-1MQ breaks this cycle by selectively inhibiting NNMT. With NNMT blocked, nicotinamide is no longer diverted toward methylation and excretion — it remains available for NAD+ synthesis. The result is a meaningful rise in intracellular NAD+ without adding more precursor substrate. This is what makes 5-Amino-1MQ such a compelling NAD+ stack companion: NMN or NR increases the supply of precursors, while 5-Amino-1MQ reduces the drain. Together, they push intracellular NAD+ higher than either can achieve alone.

• 1 NNMT inhibition — the single upstream target. NNMT (nicotinamide N-methyltransferase) catalyzes the methylation of nicotinamide using S-adenosylmethionine (SAM) as a methyl donor, producing 1-methylnicotinamide (1-MNA). In people with obesity or metabolic dysfunction, NNMT activity in adipose tissue is dramatically elevated — up to four times higher than in lean individuals. 5-Amino-1MQ is a potent, selective competitive inhibitor of NNMT. By occupying the active site, it prevents nicotinamide from being converted into 1-MNA, preserving it for NAD+ biosynthesis instead.
• 2 Intracellular NAD+ elevation — without adding more precursor. Because 5-Amino-1MQ reduces the rate at which nicotinamide is diverted from the NAD+ synthesis pathway, it raises intracellular NAD+ concentrations in the tissues where NNMT is most active — particularly adipose tissue and liver. This is mechanistically distinct from NMN or NR, which increase the supply of precursor substrate. 5-Amino-1MQ reduces the drain. This is why the combination is so effective: push and pull on the same pipeline from both ends simultaneously.
• 3 Adipocyte apoptosis and fat cell reduction. In adipose tissue, elevated NNMT suppresses key metabolic signals that normally regulate fat cell size and survival. When NNMT is inhibited by 5-Amino-1MQ, intracellular signaling in fat cells shifts toward apoptosis — programmed cell death. In mouse models of diet-induced obesity, 5-Amino-1MQ administration produced significant reductions in body weight and fat mass without caloric restriction, and without the lean mass loss typically associated with GLP-1-driven weight reduction. This selective adipocyte targeting is one of 5-Amino-1MQ's most clinically interesting properties.
• 4 SAM conservation and methylation balance. NNMT consumes SAM (S-adenosylmethionine) as its methyl donor. SAM is the universal methyl donor for hundreds of methylation reactions in the cell, including DNA methylation, histone methylation, and neurotransmitter synthesis. When NNMT is overactive, it competes with these other critical methylation processes for the available SAM pool. Inhibiting NNMT with 5-Amino-1MQ preserves SAM availability, potentially improving methylation capacity across these broader biological processes — a secondary benefit with implications for epigenetic aging and neurological function.